| UHC UMR Medical and Drug | FcRn Blockers (Rystiggo®, Vyvgart®, & Vyvgart Hytrulo®) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Gamifant® (Emapalumab-Lzsg) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Gastrointestinal Motility Disorders, Diagnosis and Treatment - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Gene Therapies for Hemophilia B – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Home Hemodialysis – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Hysterectomy – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Implanted Electrical Stimulator for the Spinal Cord – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Interspinous Fusion and Decompression Devices – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Ketalar® (Ketamine) and Spravato® (Esketamine) – Commercial Medical Benefit Drug Policy | 2026-01-01 |